ELECT 24 Top Ad

Earnings Speculators Bet on Big Moves for Biogen Stock

Analysts are extremely optimistic toward the pharma name

Managing Editor
Oct 22, 2018 at 11:39 AM
facebook X logo linkedin


Shares of Biogen Inc (NASDAQ:BIIB) are hovering around breakeven today at $318.97, as traders gear up for the company's third-quarter earnings report. The pharma name is scheduled to report before the market opens this Tuesday, Oct. 23, and speculative traders are banking on a much bigger-than-usual post-event price swing for BIIB stock.

On the charts, BIIB has had a volatile run in 2018. The stock fell as low as $249.17 on April 24, but bounced back to hit a three-year peak of $388.67 as soon as July 25. As a result, a 50% Fibonacci retracement of the aforementioned annual low and multi-year high rests at $318.92 -- just pennies below the stock's current trading levels, and in line with BIIB's year-to-date breakeven mark of $318.57.

Daily Chart of BIIB

Digging into its earnings history, BIIB closed higher the day after reporting in six of the last eight quarters, including the last three in a row. Looking broader, the shares have averaged a 2.6% move the day after earnings over the last two years, regardless of direction. This time around, BIIB options traders are expecting nearly four times that average move, with a 10.6% swing priced in for Tuesday's trading.

Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows BIIB with a 10-day put/call volume ratio of 1.43, which ranks in the 96th percentile of its annual range. This suggests that puts have been purchased over calls at a near-annual high pace during the past two weeks, with traders showing a distinct preference for bearish bets on BIIB ahead of earnings.

Conversely, analyst sentiment has been extremely optimistic toward the drug stock. This is per the overwhelming 18 of 24 brokerage firms that sport a "buy" or better rating. Plus, BIIB's average 12-month price target of $390.88 stands at a 22.5% upside to current levels.

Given the technical significance of the $318-$319 neighborhood where the stock is currently trading, traders will certainly be watching this area closely in the aftermath of BIIB's quarterly results. And with sentiment polarized ahead of earnings, the stage could be set for an extreme move in one direction or the other in the wake of the report.

 

Biden’s government just announced a new government "stimulus program"...

And it could hand you a payment for as much as $7,882 — each quarter.

See, it has to do with a recent 19-page memo from Biden’s office...

Directing the government to once again send a form of "stimulus payments" to the mailboxes of Americans during these difficult times.

Better still, you can collect these payouts every single quarter — for life...

Payments run as high as $7,882... And it only takes five minutes to sign up.

I call this the "Stimulus Stipends" program…

And Forbes recently declared that you can "retire rich" thanks to this program.

So if you want to start cashing in your quarterly payouts — courtesy of the U.S government...

Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here. 
 (ad)
 

election 2024 report

                                                  AD                                                  
best AI trade you can make today…?
(it’s not MSFT, GOOGL, AMZN or AAPL)

                                                  AD                                                  

 
 

VOLATILITY SCORECARD

 


                                               AD                                                    
Crazy Opportunity!! Tiny AI Stock just $3
“This Type of AI Will Be Worth “Ten MSFTs.”

                                               AD                                                    

 
4 AI STOCKS TO BUY NOW
 

                                                  AD                                                  
best AI trade you can make today…?
(it’s not MSFT, GOOGL, AMZN or AAPL)

                                                  AD